CA2288631A1 - Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie - Google Patents

Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie Download PDF

Info

Publication number
CA2288631A1
CA2288631A1 CA002288631A CA2288631A CA2288631A1 CA 2288631 A1 CA2288631 A1 CA 2288631A1 CA 002288631 A CA002288631 A CA 002288631A CA 2288631 A CA2288631 A CA 2288631A CA 2288631 A1 CA2288631 A1 CA 2288631A1
Authority
CA
Canada
Prior art keywords
cells
active substance
sensory
space
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002288631A
Other languages
English (en)
Inventor
Marion Sangster Eckmiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TD VERWALTUNGS GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2288631A1 publication Critical patent/CA2288631A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'un principe actif influant sur l'homéostasie du calcium de cellules pour traiter les dégénérescences de cellules sensorielles et de cellules adjacentes.
CA002288631A 1997-05-05 1998-04-02 Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie Abandoned CA2288631A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19718826.5 1997-05-05
DE1997118826 DE19718826A1 (de) 1997-05-05 1997-05-05 Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
PCT/EP1998/001951 WO1998050065A2 (fr) 1997-05-05 1998-04-02 Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie

Publications (1)

Publication Number Publication Date
CA2288631A1 true CA2288631A1 (fr) 1998-11-12

Family

ID=7828596

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002288631A Abandoned CA2288631A1 (fr) 1997-05-05 1998-04-02 Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie

Country Status (5)

Country Link
EP (1) EP0980256A2 (fr)
AU (1) AU7641798A (fr)
CA (1) CA2288631A1 (fr)
DE (1) DE19718826A1 (fr)
WO (1) WO1998050065A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259775B2 (en) * 2000-05-12 2006-07-13 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
WO2020036658A3 (fr) * 2018-04-27 2020-04-02 The Johns Hopkins University Médicaments favorisant la survie des photorécepteurs du bâtonnet rétinien
US11040019B2 (en) 2016-08-19 2021-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322854A1 (fr) 1998-03-05 1999-09-10 Jun Inoue Composition pharmaceutique pour la prophylaxie et la therapie de maladies associees a des modifications cytopathiques des tissus du fond de l'oeil
FR2784030B1 (fr) * 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
ATE446948T1 (de) * 2003-12-12 2009-11-15 Senju Pharma Co Alpha-ketoamidderivativ, herstellungsverfahren und verwendung davon
JP4758641B2 (ja) * 2003-12-12 2011-08-31 千寿製薬株式会社 α−ケトアミド誘導体、その製造方法、及びその用途
DE102009056597A1 (de) * 2009-12-02 2011-06-09 Tobias Brockmann Verwendung von Flavin-Derivaten zur Behandlung von Pathologien an der Membrana limitans interna (ILM)

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995057A (en) * 1974-04-19 1976-11-30 Wilhelm Horrmann Ophthalmological method
US4188394A (en) * 1978-05-08 1980-02-12 Nelson Research & Development Company Ophthalmic composition and method of use
SU1297862A1 (ru) * 1980-07-03 1987-03-23 Институт цитологии и генетики СО АН СССР Средства дл лечени пигментной дегенерации сетчатки
JPS5718609A (en) * 1980-07-08 1982-01-30 Senjiyu Seiyaku Kk Intraocular hypotensor
JPS5732229A (en) * 1980-08-05 1982-02-20 Eiji Sakata Preventing agent against kinesia
JPS57130923A (en) * 1981-02-07 1982-08-13 Eiji Sakata Remedy and preventive for vertigo
CH658595A5 (de) * 1983-08-17 1986-11-28 Inst Khim Fiz An Sssr Retinoprotektor zur behandlung von augenerkrankungen.
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
WO1990006118A1 (fr) * 1988-12-05 1990-06-14 Houston Biotechnology Incorporated Utilisation therapeutique de dihydropyrimidones et de derives de benzazepine et de benzothiazepine dans le disfonctionnement du nerf optique ou retinien
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5260059A (en) * 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US5156852A (en) * 1989-04-20 1992-10-20 La Haye Laboratories, Inc. Composition and method for combating macular degeneration
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
JPH04178328A (ja) * 1990-11-08 1992-06-25 Unitika Ltd 血管新生阻害剤
JPH04182432A (ja) * 1990-11-19 1992-06-30 Toshio Tanaka カルシウム依存性環状ヌクレオチドホスホジエステラーゼ阻害剤
WO1993010798A1 (fr) * 1991-12-04 1993-06-10 Uab Research Foundation Anticorps monoclonal dirige contre la molecule d'adhesion des cellules gliales et procede d'utilisation
US5252568A (en) * 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with loxapine
US5266580A (en) * 1992-01-24 1993-11-30 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with droperidol
EP0671879B1 (fr) * 1992-02-14 2000-05-24 Regeneron Pharmaceuticals, Inc. Prevention des lesions et de la degenerescence des photorecepteurs par des facteurs neurotrophiques
CN1077092A (zh) * 1992-04-10 1993-10-13 张勇 一种眼保健饮料的制备方法
CN1082896A (zh) * 1992-07-18 1994-03-02 苏州第六制药厂 止晕栓制备方法
JPH06234645A (ja) * 1993-02-09 1994-08-23 Toagosei Chem Ind Co Ltd 血管新生阻害剤
SE9301422D0 (sv) * 1993-04-28 1993-04-28 Kabi Pharmacia Ab Method and means for inhibiting posterior capsule opacification
US5421818A (en) * 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
US5424321A (en) * 1993-12-08 1995-06-13 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
PT682664E (pt) * 1993-12-08 2001-06-29 Alcon Laboratoires Inc Compostos possuindo actividade potente como antagonistas do calcio e anti-oxidantes e sua utilizacao como agentes citoprotectores
JP2759050B2 (ja) * 1994-01-27 1998-05-28 住友製薬株式会社 突発性難聴治療用医薬組成物
CN1057444C (zh) * 1994-03-16 2000-10-18 吴生武 治疗近视眼药水
WO1995034302A2 (fr) * 1994-06-16 1995-12-21 Allergan Procede utile pour reduire la pression intraoculaire dans l'×il mammalien a l'aide de composes chelatant le calcium
EP0785196B1 (fr) * 1995-03-28 2000-06-21 Ferrer Internacional, S.A. Polymorphes a et b de 1-(diphenylmethyl)-4-[3-(2-phenyle-1,3-dioxolan-2-yle)propyle]piperazine
JPH11505239A (ja) * 1995-05-19 1999-05-18 ユニバーシティ オブ イースト アングリア カルシウム細胞内貯蔵不活性化剤及びその処方物の細胞成長抑制剤としての使用方法
EP0840614A1 (fr) * 1995-06-13 1998-05-13 Sanofi Winthrop, Inc. Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives
ATE230389T1 (de) * 1995-10-25 2003-01-15 Senju Pharma Co Angiogenese inhibitoren
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
US6303579B1 (en) * 1996-10-31 2001-10-16 Alcon Laboratories, Inc. Use of calpain inhibitors to treat ocular neural pathology
IT1288399B1 (it) * 1996-12-03 1998-09-22 Sigma Tau Ind Farmaceuti Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259775B2 (en) * 2000-05-12 2006-07-13 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
US11040019B2 (en) 2016-08-19 2021-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
WO2020036658A3 (fr) * 2018-04-27 2020-04-02 The Johns Hopkins University Médicaments favorisant la survie des photorécepteurs du bâtonnet rétinien

Also Published As

Publication number Publication date
WO1998050065A2 (fr) 1998-11-12
EP0980256A2 (fr) 2000-02-23
WO1998050065A3 (fr) 1999-06-10
DE19718826A1 (de) 1998-11-12
AU7641798A (en) 1998-11-27

Similar Documents

Publication Publication Date Title
Honjo et al. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery
Beuerman et al. Sensory denervation of the rabbit cornea affects epithelial properties
US6001386A (en) Implantable controlled release device to deliver drugs directly to an internal portion of the body
US7621907B2 (en) Implantable drug delivery system
Havenith et al. Spiral ganglion cell survival after round window membrane application of brain-derived neurotrophic factor using gelfoam as carrier
US20060142213A1 (en) Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
JP2002515009A (ja) 緑内障治療において水様液の流出を強化する方法
JPH0648901A (ja) 血清フリーの医療溶液のための方法および装置
Besharse et al. Rod photoreceptor disc shedding in eye cups: relationship to bicarbonate and amino acids
US5036046A (en) Method for enhancing healing of corneal endothelial wounds
KR20010073181A (ko) 나트륨 이뇨 펩티드를 유효 성분으로하는 누액 분비 촉진또는 각결막 장해 치료용 점안제
Sharif i Drugs and i devices discovery research: preclinical assays, techniques, and animal model studies for ocular hypotensives and neuroprotectants
US5051443A (en) Method for enhancing healing of corneal endothelial wounds
CA2288631A1 (fr) Utilisation de principes actifs a effet biologique pour influer sur l'espace extracellulaire de cellules sensorielles et procede de commande d'administration de principe actif et dispositif approprie
Scuderi et al. Melatonin: implications for ocular disease and therapeutic potential
Stumpff et al. Characterization of maxi-K-channels in bovine trabecular meshwork and their activation by cyclic guanosine monophosphate.
US20070129441A1 (en) Protection of cells from adverse external or intrinsic effects, cellular degeneration and death by n-acylethanolamines
Epstein et al. Nonsulfhydryl-reactive phenoxyacetic acids increase aqueous humor outflow facility.
US20100303887A1 (en) DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells
Mahmoud et al. Lensectomy and vitrectomy decrease the rate of photoreceptor loss in rhodopsin P347L transgenic pigs
KR20150083167A (ko) 메틸렌 블루를 포함하는 감각신경성 난청의 치료 또는 예방용 약학 조성물
Ohtsuka et al. Divergent axon collaterals from the rostral superior colliculus to the pretectal accommodation‐related areas and the omnipause neuron area in the cat
US5032575A (en) Method for enhancing healing of corneal endothelial wounds
JP2001504469A (ja) モルフォゲン・ペプチド誘発による感覚認知組織の再生
RU2733392C1 (ru) Комбинированное офтальмологическое средство

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20040402